Veracyte Inc (VCYT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Veracyte Inc stock (VCYT) is currently trading at $32.79. Veracyte Inc PE ratio is 41.17. Veracyte Inc PS ratio (Price-to-Sales) is 5.06. Analyst consensus price target for VCYT is $47.50. WallStSmart rates VCYT as Hold.
- VCYT PE ratio analysis and historical PE chart
- VCYT PS ratio (Price-to-Sales) history and trend
- VCYT intrinsic value — DCF, Graham Number, EPV models
- VCYT stock price prediction 2025 2026 2027 2028 2029 2030
- VCYT fair value vs current price
- VCYT insider transactions and insider buying
- Is VCYT undervalued or overvalued?
- Veracyte Inc financial analysis — revenue, earnings, cash flow
- VCYT Piotroski F-Score and Altman Z-Score
- VCYT analyst price target and Smart Rating
Veracyte Inc
📊 No data available
Try selecting a different time range
VCYT Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Veracyte Inc (VCYT)
VCYT is trading near its Graham intrinsic value of $37.44, suggesting the stock is reasonably priced at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Veracyte Inc (VCYT) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, eps growth, institutional own.. Concerns around return on equity. Fundamentals are solid but monitor weak areas for improvement.
Veracyte Inc (VCYT) Key Strengths (4)
Earnings per share surging 712.00% year-over-year
110.83% of shares held by major funds and institutions
Trading at 1.93x book value, attractively priced
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Veracyte Inc (VCYT) Areas to Watch (5)
Low profitability relative to shareholder equity
Premium valuation at 5.1x annual revenue
Decent operational efficiency, solid but not exceptional
Solid revenue growth at 18.50% per year
Decent profitability, keeps $13 per $100 revenue
Supporting Valuation Data
Veracyte Inc (VCYT) Detailed Analysis Report
Overall Assessment
This company scores 59/100 in our Smart Analysis, earning a C grade. Out of 9 metrics analyzed, 4 register as strengths (avg 8.8/10) while 5 fall into concern territory (avg 5.0/10). All four categories (Growth, Profitability, Valuation, and Quality) show healthy scores, indicating broadly sound fundamentals.
The Bull Case
The strongest argument centers on EPS Growth, Institutional Own., Price/Book. Valuation metrics including Price/Book (1.93) suggest the stock is attractively priced. Growth metrics are encouraging with EPS Growth at 712.00%.
The Bear Case
The primary concerns are Return on Equity, Price/Sales, Operating Margin. Some valuation metrics including Price/Sales (5.06) suggest expensive pricing. Growth concerns include Revenue Growth at 18.50%, which may limit upside. Profitability pressure is visible in Return on Equity at 5.34%, Operating Margin at 17.50%, Profit Margin at 12.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 5.34% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 18.50% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (EPS Growth, Institutional Own.) and negatives (Return on Equity, Price/Sales). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
VCYT Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
VCYT's Price-to-Sales ratio of 5.06x trades at a deep discount to its historical average of 16.45x (6th percentile). The current valuation is 95% below its historical high of 96.19x set in Dec 2013, and 20% above its historical low of 4.23x in Apr 2024.
Compare VCYT with Competitors
Top DIAGNOSTICS & RESEARCH stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Veracyte Inc (VCYT) · HEALTHCARE › DIAGNOSTICS & RESEARCH
The Big Picture
Veracyte Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 517M with 19% growth year-over-year. Profit margins of 12.8% are healthy, with room for further expansion as the business scales.
Key Findings
Generating 48M in free cash flow and 53M in operating cash flow. Earnings are translating into actual cash generation.
Debt-to-equity ratio of 0.03 indicates a conservative balance sheet with 316M in cash.
What to Watch Next
Margin expansion: can Veracyte Inc push profit margins above 15% as the business scales?
Volatility is elevated with a beta of 1.96, so expect amplified moves relative to the broader market.
Sector dynamics: monitor DIAGNOSTICS & RESEARCH industry trends, competitive moves, and regulatory changes that could impact Veracyte Inc.
Bottom Line
Veracyte Inc offers an attractive blend of growth (19% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Veracyte Inc(VCYT)
NASDAQ
HEALTHCARE
DIAGNOSTICS & RESEARCH
USA
Veracyte, Inc. is a genomic diagnostics company in the United States and internationally. The company is headquartered in South San Francisco, California.